HP cohorts, SAD
TG
Reductions in fasting TG concentrations were observed starting at day 3 and sustained until the end of the study. Median percentage change from baseline to day 85 ranged from −16.6% to −54.4% for the 35-mg and 300-mg doses, respectively, compared to −2.6% for placebo. VLDL-C concentrations decreased, with mean (s.d.) percentage change from baseline at day 85 ranging from −8.8% (23.4%) to −51.7% (24.8%) for the 35-mg and 300-mg doses, respectively, compared to 12.3% (36.4%) for pooled placebo (Extended Data Fig. Mean (s.d.) percentage change from baseline in non-HDL-C at day 85 ranged from −28.7% (8.5%) to −17.5% (29.4%) for the 100-mg and 200-mg doses, respectively, compared to −4.6% (12.6%) for placebo (Extended Data Fig. At day 85, LDL-C mean (s.d.) percentage change from baseline ranged from −26.8% (9.5%) to 4.1% (61.1%) for 100-mg and 200-mg doses, respectively, compared to 0.3% (26.8%) for pooled placebo (Extended Data Fig. Mean (s.d.) percentage change from baseline in HDL-C at day 85 ranged from 2.5% (24.6%) to −12.9% (21.1%) for the 100-mg and 300-mg doses, respectively, compared to 6.9% (11.5%) in pooled placebo (Extended Data Fig. Results from MMRM analysis (least squares (LS) mean difference and LS mean difference versus placebo) for ANGPTL3, TG, non-HDL-C, VLDL-C, LDL-C, HDL-C and ApoB at day 85 are presented in Table Full results (mean percentage change from baseline, MMRM analysis) for other lipids/lipoproteins at day 85 are presented in Extended Data Table 